Arcus Biosciences PE Ratio 2017-2022 | RCUS

Current and historical p/e ratio for Arcus Biosciences (RCUS) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Arcus Biosciences PE ratio as of September 23, 2022 is 35.51.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Arcus Biosciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-26 24.52 34.54
2022-06-30 25.34 $0.71 35.69
2022-03-31 31.56 $0.55 57.38
2021-12-31 40.47 $0.43 94.12
2021-09-30 34.87 $-4.10 0.00
2021-06-30 27.46 $-2.96 0.00
2021-03-31 28.08 $-2.80 0.00
2020-12-31 25.96 $-2.35 0.00
2020-09-30 17.14 $-1.91 0.00
2020-06-30 24.74 $-2.45 0.00
2020-03-31 13.88 $-2.16 0.00
2019-12-31 10.10 $-1.94 0.00
2019-09-30 9.10 $-1.84 0.00
2019-06-30 7.95 $-1.58 0.00
2019-03-31 12.49 $-1.26 0.00
2018-12-31 10.77 $-2.22 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.819B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00